Want to see GB:4BB full AI Analyst Report?
Top Page
4basebio UK Societas
(LSE:4BB)
Select Model
Select Model
Rating:52Neutral
Price Target:
561.00 p
▲(18.11% Upside)
Action:Reiterated
Date:09/22/26
The score is held back primarily by weak financial performance—widening losses, sustained and accelerating cash burn, and a weakening balance sheet with higher leverage and lower equity. Technicals provide partial support as the stock is above major moving averages, but overbought momentum (RSI > 80) adds near-term risk. Valuation remains constrained by negative earnings (negative P/E) and no stated dividend yield.
Positive Factors
Synthetic DNA positioning
The company is positioned in a specialized enabling segment of biotechnology, supplying synthetic DNA and related capabilities for gene therapies, vaccines, and genetic medicines. This focus gives the business a clear role in supporting biopharma development and manufacturing workflows over the medium term.
Negative Factors
Persistent and widening losses
The combination of declining 2025 revenue and materially wider losses shows that the business has not yet converted its technology and revenue base into sustainable profitability. Negative operating and net margins leave limited internal funding capacity and make earnings improvement dependent on renewed growth or cost control.
Read all positive and negative factors
Positive Factors
Negative Factors
Synthetic DNA positioning
The company is positioned in a specialized enabling segment of biotechnology, supplying synthetic DNA and related capabilities for gene therapies, vaccines, and genetic medicines. This focus gives the business a clear role in supporting biopharma development and manufacturing workflows over the medium term.
Read all positive factors
4basebio UK Societas (4BB) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£87.10M
Dividend YieldN/A
Average Volume (3M)1.29K
Price to Earnings (P/E)―
Beta (1Y)-0.22
Revenue Growth-56.10%
EPS Growth-16.77%
CountryUK
Employees140
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.16
Shares Outstanding15,538,518
10 Day Avg. Volume815
30 Day Avg. Volume1,292
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)9.43
Price to Sales (P/S)56.33
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,000.00Price Target Upside110.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1
Revenue Forecast (FY)£2.60M
4basebio UK Societas Business Overview & Revenue Model
Company Description
4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral vector solu...
4basebio UK Societas Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 781.00K | 1.69M | 933.00K | 506.00K | 268.00K | 338.00K |
| Gross Profit | -679.00K | 548.00K | 630.00K | 340.00K | 239.00K | 269.00K |
| EBITDA | -16.30M | -15.58M | -10.97M | -7.34M | -5.41M | -3.21M |
| Net Income | -18.02M | -16.91M | -12.33M | -7.67M | -5.15M | -3.23M |
Balance Sheet | ||||||
| Total Assets | 27.12M | 29.55M | 44.73M | 11.92M | 11.69M | 14.70M |
| Cash, Cash Equivalents and Short-Term Investments | 14.05M | 17.80M | 34.60M | 3.07M | 4.35M | 9.59M |
| Total Debt | 23.10M | 16.50M | 15.22M | 10.46M | 3.35M | 1.76M |
| Total Liabilities | 25.84M | 19.44M | 18.35M | 12.41M | 4.57M | 3.01M |
| Stockholders Equity | 1.27M | 10.11M | 26.38M | -492.00K | 7.12M | 11.70M |
Cash Flow | ||||||
| Free Cash Flow | -16.57M | -15.21M | -12.31M | -7.67M | -6.64M | -4.25M |
| Operating Cash Flow | -15.36M | -14.75M | -10.74M | -6.18M | -4.70M | -2.74M |
| Investing Cash Flow | -2.44M | -1.64M | -1.57M | -1.49M | -1.94M | -1.51M |
| Financing Cash Flow | 5.83M | -369.00K | 43.87M | 6.42M | 1.24M | -467.00K |
4basebio UK Societas Technical Analysis
Positive
475.00
Price Trends
514.73
Positive
519.64
Positive
526.74
Positive
Market Momentum
16.76
Positive
82.64
Negative
59.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:4BB, the sentiment is Positive. The current price of 475 is below the 20-day moving average (MA) of 545.63, below the 50-day MA of 514.73, and below the 200-day MA of 526.74, indicating a bullish trend. The MACD of 16.76 indicates Positive momentum. The RSI at 82.64 is Negative, neither overbought nor oversold. The STOCH value of 59.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:4BB.
4basebio UK Societas Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | £94.57M | 12.75 | 65.83% | 8.29% | -8.21% | -5.27% | |
52 Neutral | £87.10M | -4.85 | -316.73% | ― | -56.10% | -16.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £311.54M | -7.02 | -1293.07% | ― | ― | ― | |
47 Neutral | £12.20M | -9.85 | -97.87% | ― | 7.38% | 44.13% | |
46 Neutral | £11.27M | -3.25 | -135.35% | ― | 13.42% | 65.63% | |
40 Underperform | £12.77M | -0.24 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:4BB
4basebio UK Societas
562.50
-197.50
-25.99%
GB:AVCT
Avacta Group plc
64.00
-7.00
-9.86%
GB:BVXP
Bioventix
1,810.00
-393.19
-17.85%
GB:OBD
Oxford BioDynamics
0.10
-0.43
-81.73%
GB:FAB
Fusion Antibodies Plc
9.75
-4.00
-29.09%
GB:APTA
Aptamer Group Plc
0.33
-0.67
-67.17%
4basebio UK Societas Corporate Events
Business Operations and StrategyProduct-Related Announcements
4basebio Boosts Synthetic DNA Capacity for Personalised mRNA Medicines
Positive
Sep 7, 2026
4basebio PLC has expanded its high quality and cGMP synthetic DNA manufacturing operations in Cambridge to support personalised mRNA medicines, enabling shorter turnaround times, smaller patient-specific batch sizes and rapid batch release. The up...
Business Operations and Strategy
4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing
Positive
Aug 26, 2026
4basebio PLC, a UK-listed biotech focused on synthetic, cell-free DNA and mRNA for advanced gene and cell therapies, develops GMP-grade DNA constructs tailored to applications such as viral vectors, genome editing, and DNA vaccines. The company po...
Business Operations and StrategyExecutive/Board Changes
4basebio awards new management share options to support long-term growth
Positive
Jul 22, 2026
4basebio PLC has granted a total of 684,872 share options to senior executives and a PDMR as part of its long-term incentive arrangements. The bulk of the options, issued to CEO Dr. Amy Walker, Executive Chair Dr. Manja Boerman and non-executive d...
Business Operations and StrategyExecutive/Board Changes
4basebio strengthens board with deep tech investor Cornel Chiriac
Positive
Jul 8, 2026
4basebio PLC has appointed Mr. Cornel Chiriac as a non-executive director with immediate effect, adding seasoned investment and deep tech venture expertise to its board. Chiriac, an investment director at MG Investments’ Crossover Fund, brin...
Business Operations and StrategyShareholder Meetings
4basebio Secures AGM Backing and Awards New Employee Share Options
Positive
Jun 30, 2026
4basebio PLC reported that all resolutions were approved at its Annual General Meeting held on 30 June 2026, confirming shareholder support for the board’s proposals. The meeting outcome reinforces governance stability as the company advance...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.